Kyowa Hakko Kogyo (OP:KYKOF)

16.79 -1.21 (-6.72%)

Streaming Delayed Price Updated: 11:09 AM EST, Mar 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Kyowa Hakko Kogyo

Citius Oncology Transitions to Commercial Stage: Analyzing the 10-K Filing and the 2026 Outlook for LYMPHIR

December 23, 2025

CRANFORD, NJ — As the 2025 calendar year draws to a close, Citius Oncology, Inc. (Nasdaq: CTOR) has reached a pivotal juncture in its corporate evolution. Following the release of its SEC 10-K filing...

Via MarketMinute

Topics Economy Regulatory Compliance

Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare ↗

June 15, 2024

Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi...

Via Talk Markets

Why Orchard Therapeutics Stock Is Soaring Today ↗

October 05, 2023

A buyout offer is fueling a rise in the company's shares today.

Via The Motley Fool

Amgen, Kyowa Kirin Ink $1.25B Deal for Developing KHK4083 In Skin Disorders ↗

June 01, 2021

Amgen Inc (NASDAQ: AMGN) and Kyowa Kirin Co Ltd (OTC: KYKOF) have agreed to jointly develop and commercialize KHK4083, Kyowa Kirin's Phase 3-ready anti-...

Via Benzinga

The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck ↗

June 07, 2021

Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,...

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.